Compare VS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VS | PPBT |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.5M |
| IPO Year | N/A | N/A |
| Metric | VS | PPBT |
|---|---|---|
| Price | $1.26 | $0.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.7K | ★ 784.3K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,179,348.00 | N/A |
| Revenue This Year | $3,459.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2281.70 | N/A |
| 52 Week Low | $1.15 | $0.53 |
| 52 Week High | $3.79 | $5.20 |
| Indicator | VS | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 45.42 |
| Support Level | $1.20 | $0.78 |
| Resistance Level | $1.47 | $0.87 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 29.29 | 14.25 |
Versus Systems Inc offers a suite of proprietary business-to-business software tools that are meant to drive user engagement through gamification and rewards. These tools allow its partners to offer in-game prizes and rewards, including merchandise, coupons, digital goods, and sweepstakes entries - inside their websites, their venues, or their streaming media content. Its customers are mostly sports teams, venues, and advertising agencies, which typically use its products as part of their live events or as part of an advertising campaign with the goal of engaging fans, increasing consented first-party data, and increasing sales. The company operates in Canada and the USA.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.